This website uses cookies. By continuing to access the site you are agreeing to their use. Learn more about cookies.

Clinigen-Logo.png
  • Mission
  • How we can help
    Pharmaceutical & Biotech Companies
    Healthcare Professionals
    Patient Groups
    Patients
  • Medicines & Services
    Commercial Medicines >
    • CARDIOXANE®
    • ETHYOL®
    • FOSCAVIR®
    • SAVENE® (Non US)
    • TOTECT® (US only)
    • Partnering with Clinigen
    Unlicensed Medicines >
    • Policy Development
    • Asset Strategy
    • Early Access
    • Real World Evidence
    • Post-Trial Access
    • Phased Launch and Non-Launch Markets
    • Medicine Shortages
    • Market Withdrawal/ Discontinuations
    • Consulting Services
    Clinical Trial Services >
    • Comparator Sourcing and Ancillary Supply
    • Direct-to-site
    • Demand Driven Labelling & Distribution
    • Investigator Initiated Trials
    • Technical Consultancy

    Cliniport Medicine Finder

    Cliniport medicine finder provides access to 10,000 licensed and unlicensed products.

    About Cliniport
  • Global offices
    Australia & New Zealand
    Japan
    Singapore
    South Africa
    United Kingdom
    United States
  • Investors
    At a Glance
    Financial Highlights
    Investment Case
    • Business Model
    • Market Overview
    • Strategy
    • Our Businesses
    Share tools
    Results, Reports and Presentations
    Quantum Archive
    Financial Calendar
    Press Releases
    • Press Releases
    • Regulatory News
    • Email Alerts
    Shareholder Services
    • AGM
    • Registrar Services
    • Major Shareholders
    • Advisor Contacts
    • Analyst Coverage
    AIM Rule 26
    Corporate Governance
    • Corporate Governance Statement
    • Board of Directors
    • Tax Strategy
  • Company
    About Clinigen >
    • History
    • Responsible business
    • Operational excellence
    • Our brands
    Careers >
    • Frequently Asked Questions
    • Apply Online
    • Privacy Notice - Applicants
    Newsroom
    • Video Library
    • Press Releases
Cliniport Medicine Finder
About Cliniport
Login
Clinigen France
Clinigen Germany
Get in touch
Get in touch
  • Mission
  • How we can help
    How we can help
    • Pharmaceutical & Biotech Companies
    • Healthcare Professionals
    • Patient Groups
    • Patients
  • Medicines & Services
    Medicines & Services
    • Commercial Medicines >
      Commercial Medicines >

      Commercial Medicines >

      • CARDIOXANE®
      • ETHYOL®
      • FOSCAVIR®
      • SAVENE® (Non US)
      • TOTECT® (US only)
      • Partnering with Clinigen
    • Unlicensed Medicines >
      Unlicensed Medicines >

      Unlicensed Medicines >

      • Policy Development
      • Asset Strategy
      • Early Access
      • Real World Evidence
      • Post-Trial Access
      • Phased Launch and Non-Launch Markets
      • Medicine Shortages
      • Market Withdrawal/ Discontinuations
      • Consulting Services
    • Clinical Trial Services >
      Clinical Trial Services >

      Clinical Trial Services >

      • Comparator Sourcing and Ancillary Supply
      • Direct-to-site
      • Demand Driven Labelling & Distribution
      • Investigator Initiated Trials
      • Technical Consultancy
  • Global offices
    Global offices
    • Australia & New Zealand
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Investors
    Investors
    • At a Glance
    • Financial Highlights
    • Investment Case
      Investment Case

      Investment Case

      • Business Model
      • Market Overview
      • Strategy
      • Our Businesses
    • Share tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      Press Releases
      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      Shareholder Services
      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      Corporate Governance
      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
  • Company
    Company
    • About Clinigen >
      About Clinigen >

      About Clinigen >

      • History
      • Responsible business
      • Operational excellence
      • Our brands
    • Careers >
      Careers >

      Careers >

      • Frequently Asked Questions
      • Apply Online
      • Privacy Notice - Applicants
    • Newsroom
      Newsroom
      • Video Library
      • Press Releases
Medicine Finder
  • About Cliniport
  • Login
Global sites
  • Clinigen France
  • Clinigen Germany

Press Releases

  • At a Glance
  • Financial Highlights
  • Investment Case
    • Business Model
    • Market Overview
    • Strategy
    • Our Businesses
  • Share tools
  • Results, Reports and Presentations
  • Quantum Archive
  • Financial Calendar
  • Press Releases
    • Press Releases
    • Regulatory News
    • Email Alerts
  • Shareholder Services
    • AGM
    • Registrar Services
    • Major Shareholders
    • Advisor Contacts
    • Analyst Coverage
  • AIM Rule 26
  • Corporate Governance
    • Corporate Governance Statement
    • Board of Directors
    • Tax Strategy
  • 2018
  • 2017
  • 2016
  • 2015
  • Archive
More
Filter by
  • 25 Jul 2018

    Clinigen acquires global rights to Imukin® from Horizon Pharma
    Related materials
    PDF (434.55KB)
  • 17 Jul 2018

    Clinigen acquires global rights to Proleukin®  outside the United States
    Related materials
    PDF (204.19KB)
  • 17 Jul 2018

    Year end trading update
    Related materials
    PDF (365.71KB)
  • 14 Jun 2018

    Clinigen signs exclusive supply & distribution agreement with Lukare  for Elliotts B® Solution
    Related materials
    PDF (198.92KB)
  • 04 Jun 2018

    Future Oncology publishes dexrazoxane article supporting EC removal of restrictions for use in children and adolescents
    Related materials
    PDF (164.16KB)
  • 31 May 2018

    Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa
    Related materials
    PDF (360.96KB)
  • 24 May 2018

    Clinigen signs agreement with Nordic Pharma for aprotinin
    Related materials
    PDF (306.54KB)
  • 22 May 2018

    Clinigen and Mitsubishi Tanabe initiate European Managed Access Program for edaravone to treat ALS
    Related materials
    PDF (195.03KB)
  • 12 Apr 2018

    Clinigen receives PBS listing for TREXJECT® (methotrexate) in Australia for the treatment of rheumatoid arthritis and psoriasis
    Related materials
    PDF (215.41KB)
  • 19 Mar 2018

    Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos® (CPX-351) outside the United States

Our global offices
  • Australia & New Zealand
  • Japan
  • Singapore
  • South Africa
  • United Kingdom
  • United States
Site
tools
  • AE Reporting
  • Medical enquiries
  • Terms of use
  • Cookies
  • Privacy policy
  • UK Gender Pay Gap Report
  • Modern Slavery Statement
  • Access Online
  • Sitemap
  • Consumer Information Obligations
Access cliniport

Cliniport medicine finder provides Healthcare Professionals with safe and secure access to 10,000 licensed and unlicensed products.

Log In About Cliniport
Subscribe to our email alerts
  • Twitter
  • Vimeo
  • Linkedin
© Copyright 2018 Clinigen Group plc. By Emperor